What will ASCO 18 do for BMS???

If you buy into bombs and bullets why not back BMS.

https://www.nasdaq.com/symbol/bmy/insider-trades

 

A lot of option execute in insider trading.

From Stat +:

"New data emerging Wednesday night, May 16, from clinical trial research abstracts released by the American Society of Clinical Oncology (ASCO) paint a muddled picture overall. Even with hints of efficacy, there’s still no convincing proof cancer patients benefit more when experimental immune-boosting drugs are paired with immunotherapy blockbusters like Merck’s Keytruda and Bristol-Myers Squibb‘s Opdivo."

 

A lot of insider trading particularly Option Execute going on there.

From Stat + (statnews.com)

"Biotech and pharma companies are racing to develop combinations of immunotherapy drugs to treat cancer more effectively. But new data emerging Wednesday night from clinical trial research abstracts released by the American Society of Clinical Oncology (ASCO) paint a muddled picture.

Even with hints of efficacy, there’s still no convincing proof cancer patients benefit more when experimental immune-boosting drugs are paired with immunotherapy blockbusters like Merck’s Keytruda and Bristol-Myers Squibb‘s Opdivo."

 

So how’s ASCO going?

 

Lots of data released as of today. Wait until weekend's over.

 

really good thanks, just off to bed now, with a friend.

 

Is this a pretty standard boilerplate quote at the early stage of a major advance in medicine?

Maybe I’ve lived too long but this quote means nothing.

Folks go all in and get euphoric over some new treatment modality (as if any one drug or modality will ever do everything for all patients) then it hits a few snags in clinical trials and folks re-write history to show how cautious and skeptical they were just in case things don’t pan out.

Of course, if things do pan out, they were right all along however the skepticism was justified by the early evidence. (You have to say that in a measured, academic tone to be credible).

Keep these statements handy for the next major medical breakthrough in the next 10-20 years. You’ll need it.

 

Merck takes the lead?

https://www.fiercepharma.com/pharma/asco-merck-clamps-down-lung-cancer-lead-keytruda-monotherapy-win

 

looks like another craptacular ASCO.

 

Should the CEO who has to sign off on everything with Opdivo, from detail aid messages to commercial partners be held responsible?

 

Looking gloomy over the horizon for BMS....

https://seekingalpha.com/news/3361349-merck-2-percent-premarket-positive-keytruda-data-bristol-myers-2-percent

 

maybe it’s a shrewd anti-takeover tactic. Screw things up so badly nobody will touch us. FYI Nektar we’re doing just fine until we acted as advisors.

 

Yes he should. He fired the chief scientific officer due to 026 trial screw-up, but Merck continues to wow and Opdivo which was predicted by analysts to hit 12 or $13BB in 2016, will never get there. Our stock has been outperformed by all 3 market indices whether you do a 1 or 5 year comparison. This is absolutely horrible and the CEO owns this. Billions in mkt cap lost and jobs are at risk because we are a takeover target now. CEO should be removed by the board.

 

Takeover target? Even Pfizer turned its nose on BMS.

 

That’s just with the CEO said publicly, and that is back when we had a share price in the mid 60s. Your comment is naïve.

 

Never say never.

BMS is not a very attractive takeover target.

 

Pfizer knew what was going on behind the scenes. Your comment is the naive one. CEO won't make the sole decision over takeover matters. There's the entire board and stockholders to contend with. Convince analysts why BMS is an attractive takeover market. This is your chance.

 

Pfizer wasn't convinced with Opdivo's data. They wanted further studies.

 

Actually they offered to take Eliquis as a swap for an oncology asset we said no. Because so many WW markets are Pfizer only now anyway, we keep the big 22, and get royalties on the rest. Problem is the royalties are tiny compared to what Pfizer are hitting now and in the future. Another great example of BMS leadership (n=1 gone now) draiping themselves in lights fantastic, totally fool the board, and only get found out 18-24 months later.